As SPAA combinations containing atorvastatin 20 mg are not approved in some countries , this post hoc analysis investigated the efficacy and safety of a proactive intervention strategy incorporating low-dose SPAA ( 5/10 or 10/10 mg ) only ( low-dose PI ) versus UC .
